Application Nr Approved Date Route Status External Links
NDA206353 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Evotaz® Is Indicated In Combination With Other Antiretroviral Agents For The Treatment Of Human Immunodeficiency Virus (hiv-1) Infection In Adults. Limitations Of Use: • Use Of Evotaz In Treatment-Experienced Patients Should Be Guided By The Number Of Baseline Primary Protease Inhibitor Resistance Substitutions [see Microbiology (12.4) ] . Evotaz Is A Two-Drug Combination Of Atazanavir, A Human Immunodeficiency Virus (hiv-1) Protease Inhibitor, And Cobicistat, A Cyp3a Inhibitor Indicated For Use In Combination With Other Antiretroviral Agents For The Treatment Of Hiv-1 Infection. (1) Limitations Of Use Use Of Evotaz In Treatment-Experienced Patients Should Be Guided By The Number Of Baseline Primary Protease Inhibitor Resistance Substitutions. (1)

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Comments